Document:

Exhibit 10.34

    

    

    
      Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item
        601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.

    

     

    

    AMENDMENT NO. 3 TO RESEARCH COLLABORATION AGREEMENT

    

    

    This Amendment No. 3 to Research Collaboration Agreement (this “Amendment”) is entered into as of this 30th day of April, 2020 (the “Amendment Date”), by and between President and Fellows of Harvard College, a charitable corporation of Massachusetts having an office at Richard A. and Susan F. Smith Campus
      Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”), and ReWalk Robotics, Ltd. a company
      existing under the laws of the State of Israel, having a place of business at 200 Donald Lynch Blvd., Marlborough, MA 01752 (“Company”).  Harvard and Company each shall be referred to herein as a “Party” and together as the “Parties.”

    

    

    WHEREAS, Harvard and Company entered into a Research Collaboration Agreement, dated as of May 16, 2016, as previously amended on May 1,
      2017, and April 1, 2018 (the “RCA” or “Research Collaboration Agreement”); and

     

    WHEREAS, Harvard and Company desire to amend the RCA as set forth below in accordance with Section 10.9 of the RCA.

    

    

    NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as
      follows:

     

    	I.	
            Amendment to the RCA.  Effective as of the Amendment Date:

          

     

    	

          	A.	
            Costs and Expenses.  The RCA is hereby amended by deleting existing Sections 3.1.3 through 3.1.7 in their entirety and replacing them with the following new Sections 3.1.5
              through 3.1.7, and adding a new Section 3.1.8, each to read as follows:

          

     

    3.1.5          [*] United States Dollars and [*] Cents (US $[*]) for 2020 to be paid as follows: one (1) initial
      quarterly installment of [*] United States Dollars and [*] Cents  (US $[*]) and three (3) subsequent quarterly installments of [*] United States Dollars (US $[*]), each of which shall be payable within forty-five (45) days of receipt of the invoice
      from Harvard for such amount.  Harvard shall issue each invoice to Company at least five (5) days prior to the start of each Calendar Quarter in 2020.

     

    3.1.6          [*] United States Dollars (US $[*]) for 2021 to be paid as follows: installment of [*] United States
      Dollars (US $[*]) and installments of [*] United States Dollars and [*] Cents  (US $[*]), each of which shall be payable within forty-five (45) days of receipt of the invoice from Harvard for such amount.  Harvard shall issue each invoice to Company
      at least five (5) days prior to the start of each Calendar Quarter in 2021.

     

    3.1.7          [*] United States Dollars (US $[*]) for 2022 to be paid as follows: four equal installments of [*] United
      States Dollars and [*] Cents (US $[*]), each installment of which shall be payable within forty-five (45) days of receipt of the invoice from Harvard for such amount.  Harvard shall issue each invoice to Company at least five (5) days prior to the
      start of each Calendar Quarter in 2022.”

     

    3.1.8          [*] United States Dollars and [*] Cents  (US $[*]) for 2023 to be paid as follows: one (1) installment of
      [*] United States Dollars and [*] Cents (US $[*]) for the first (1st) Calendar Quarter of 2023, such installment shall be payable within forty-five (45) days of receipt of the invoice from Harvard for such amount.  Harvard shall issue each invoice to
      Company at least five (5) days prior to the start of the first (1st) Calendar Quarter in 2023.”

     

    
      
        

    

     

    	

          	B.	
            Term.  The RCA is hereby amended by deleting the existing Section 9.1 in its entirety and replacing it with the following new Section 9.1 to read as follows:

          

     

    “9.1          Term.  This Agreement shall commence on the Effective Date and shall remain in effect
      for a period of six (6) and three-quarter (3/4) years, until February 16, 2023. (the “Term”), unless earlier terminated in accordance with the provisions of this Article 9.”

     

    	II.	
            Capitalized terms used but not otherwise defined in this Amendment shall have the respective meanings ascribed to such terms in the RCA.

          

     

    	III.	
            Except as expressly amended hereby, all other terms of the RCA shall remain unchanged and in full force and effect in accordance therewith.

          

     

    	IV.	
            This Amendment will be governed by, and construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision.

          

     

    	V.	
            The Parties may execute this Amendment in two or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.  Transmission by facsimile or electronic mail of an
              executed counterpart of this Amendment shall be deemed to constitute due and sufficient delivery of such counterpart.  If by electronic mail, the executed Amendment must be delivered in a .pdf format.

          

     

    ** Signature Page Follows **

     

    

     

    

    2

    

    
      
        

    

    

    

    IN WITNESS WHEREOF, each Party has caused this Amendment to be executed by its duly authorized representative as of the
      Amendment Effective Date.

    

    

    	
            President and Fellows of Harvard College

            By: /s/ Isaac T. Kohlberg

            Name: Isaac T. Kohlberg

            

              Title: Senior Associate Provost

              Chief Technology Development Officer

              Office of Technology Development

              Harvard University

          	
            ReWalk Robotics, Ltd.

            By: /s/ Larry Jasinski

            Name: Larry Jasinski

            Title: Chief Executive Officer

          

    

    

    I, the undersigned, hereby confirm that I have read this Amendment, including the Research Plan included in this Amendment, that its contents are acceptable to me and that I will act in accordance
      with its terms.

    

    

    /s/ Conor J. Walsh

      Conor J. Walsh, Ph.D.

     

    

     

    

    3

    

    
      
        

    

    

    

    SCHEDULE I

    

    

    Exhibit A

    

    

    Research Plan

    

    

    	Aim:	
            Harvard expects to perform research to support Company’s development of both stroke and multiple sclerosis (“MS”) specific Soft Exosuits as follows:

          

     

    [*]

    
      

      

      4Kristina Salen Offer Letter

		

			

		

		
			
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			June 22nd, 2020
		

		
			﻿
		

		
			﻿
		

		
			Kristina Salen
		

		
			﻿
		

		
			﻿
		

		
			Dear Kristina:
		

		
			﻿
		

		
			World Wrestling Entertainment, Inc. (“WWE”) is happy to extend the following offer of employment to you:
		

		
			﻿
		

		
			Title:CFO Consultant  
		

		
			Chief Financial Officer -  Effective no later than July 30th, 2020 
		

		
			﻿
		

		
			Location:1241 E. Main Street,  Stamford, CT 06902
		

		
			﻿
		

		
			Department:Finance
		

		
			﻿
		

		
			Reports to:Vince McMahon
		

		
			Chairman of the Board & CEO
		

		
			﻿
		

		
			Start Date:July 6th, 2020
		

		
			﻿
		

		
			Compensation and Benefits
		

		
			﻿
		

		
			Base Salary:   The starting base salary is $730,000 annually, less withholding, which will be paid bi-weekly. 
		

		
			﻿
		

		
			Merit Increases:   All merit increases will be paid out in accordance with our merit pay-out schedule.
		

		
			﻿
		

		
			Incentive Bonus:   You are eligible to participate in the WWE Bonus Plan. The funding of the plan is based upon the Company’s achievement of financial and/or strategic performance measures, as determined by the WWE in its discretion. The bonus pool funding can increase, decrease or be forfeited based on the level of achievement of the performance measures. The target bonus for your position is 50% of your base salary. Your individual award will be determined based upon your performance appraisal score and management discretion. The terms of any bonus eligibility can be modified or deleted at any time within WWE’s sole discretion.
		

		
			﻿
		

		
			WWE Equity:   Conditional upon full Board approval, you will be granted restricted stock units of Class A Common Stock of WWE valued at $500,000, to be received on your official start date. These restricted stock units (less applicable taxes and other deductions required by law) will vest in equal annual installments over three years, at all times subject to and governed by the terms of the Company’s Omnibus Incentive Plan (“OIP”). These shares, as well as future shares, may also be subject to the 
		

		 

 

		

			

		

		Company’s stock ownership guidelines, and at all times, all other terms and conditions of your eligibility for equity shall be governed by the plan.
		

		
			 
		

		
			You will also be considered for eligibility in all future stock programs that are offered to other key executives in the Company, including the Performance Stock Unit (PSU) program, at all times subject to management’s and the Compensation Committee’s discretion and at all times subject to the, terms and conditions of your eligibility for equity. The equity grant is typically determined as a percentage of base salary; which is 70% for your management level and remains subject to management and the Compensation Committee’s discretion.   
		

		
			﻿
		

		
			Benefits:   You will be eligible for full company benefits on the first day of the month coincident or following your date of hire. WWE benefits include (but are not limited to): medical, dental, life and disability. To help you build a financially secure future, you will be automatically enrolled in our 401k plan at 3%. Should you elect to opt out of the 401k auto-enrollment, please call Fidelity at 1-800-835-5097, after you receive their confirmation letter. WWE currently matches fifty percent (50%) of your contributions up to six percent (6%) of salary. This match is subject to a one-year vesting and may be changed by the Company at any time within WWE’s sole discretion.
		

		
			﻿
		

		
			Vacation:   Four  (4) weeks’ vacation and two  (2) personal days for the calendar year of 2020. Vacation accrual and use subject to WWE policy then in force.
		

		
			﻿
		

		
			Severance:   If at any time your employment is terminated by WWE for any or no reason, or if you resign for "good reason"  (defined as material permanent reduction in base salary; material diminution in authority, duties or responsibilities; no longer reporting directly to CEO; relocation of your principal workplace that increases your commute by more than 50 miles; or material breach of this offer letter), but without “cause” as “cause” is defined by the company’s then current Severance Policy, you will receive your then current base salary (payable in accordance with WWE’s regular payroll practices) and benefits continuation for nine (9) months from your termination date.  However, if, at the time of your termination, the then current Company severance policy would entitle you to receive more than nine (9) months of salary and benefits, you will be entitled to receive the greater package of severance.  If you resign from your employment with WWE for “good reason”, you are required to provide WWE notice of the existence of the “good reason” condition within a period not to exceed 90 days of its initial existence, and WWE shall have a period of at least 30 days during which it may cure the “good reason” condition.  If the event constituting “good reason” is not cured by WWE within the cure period, then you may resign on account of the “good reason” at any time following the end of the cure period.  Any and all severance and benefit continuation at any time is expressly conditioned on your execution of an agreement containing a release of claims in favor of WWE broadly defined, as well as other obligations to the Company referenced as conditions to receiving continued salary and benefits in the then current company Severance Policy.
		

		
			﻿
		

		
			Work Week:   While the standard work week is 40 hours per week, such hours are subject to business needs as determined by management in its discretion. As an exempt employee, your salary covers all hours worked during any given work week or 
		

		 

 

		

			

		

		other time period. You are further expected to work all hours necessary to meet the requirements of your position.
		

		
			﻿
		

		
			Acceptance and Onboarding
		

		
			﻿
		

		
			This offer is contingent upon satisfactory reference and background checks and compliance with all Immigration Control and Reform Act requirements. At all times, your employment relationship with WWE will be “at-will.” This means that either you or WWE can end your employment at any time, for any or no reason.
		

		
			﻿
		

		
			Please indicate your acceptance by signing below and sending a copy of this entire letter to Brad Kogut via email at brad.kogut@wwecorp.com by Wednesday,  June 24th,   2020.
		

		
			﻿
		

		
			Following acceptance of this offer, as it gets closer to your start date, you will receive a communication granting you access to our Workday HR system where you will have the opportunity to review and sign our policies and procedures.
		

		
			﻿
		

		
			On behalf of WWE, we are very pleased that you have accepted this offer and look forward to having you join our team.
		

		
			﻿
		

		
			Sincerely,
		

		
			﻿
		

		
			/s/  James Johnstone
		

		
			James Johnstone
		

		
			Senior Vice President, Human Resources
		

		
			﻿
		

		
			﻿
		

		
			/s/ Kristina SalenJune 22, 2020
		

		
			__________________________________________________
		

		
			Kristina SalenDate

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]